Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the heterogeneity of smoldering multiple myeloma (SMM) and challenges in diagnosing patients. Dr Ghobrial also explains how genomic and epigenetic information can help clinicians better understand a patient’s risk of progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.